Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Krishnaswamy, R. Kanteti, J. Duke-Cohan, Sivakumar Loganathan, Wanqing Liu, P. Ma, M. Sattler, P. Singleton, N. Ramnath, F. Innocenti, D. Nicolae, Ouyang Zheng, Jie Liang, J. Minna, M. Kozloff, M. Ferguson, V. Natarajan, Yi-Ching Wang, Joe Garcia, E. Vokes, R. Salgia (2009)
Ethnic Differences and Functional Analysis of MET Mutations in Lung CancerClinical Cancer Research, 15
C. Lee, Chris Brown, R. Gralla, V. Hirsh, S. Thongprasert, C. Tsai, E. Tan, J. Ho, D. Chu, Adel Zaatar, Jemela Sanchez, V. Vu, J. Au, A. Inoue, S. Lee, V. Gebski, J. Yang (2013)
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Journal of the National Cancer Institute, 105 9
B. Alter (2003)
Cancer in Fanconi anemia, 1927–2001Cancer, 97
M. Bogliolo, B. Schuster, C. Stoepker, Burak Derkunt, Yan Su, A. Raams, J. Trujillo, J. Minguillón, M. Ramírez, Roser Pujol, J. Casado, Rocío Baños, P. Río, Kerstin Knies, S. Zuniga, J. Benítez, J. Bueren, N. Jaspers, O. Schärer, J. Winter, D. Schindler, J. Surrallés (2013)
Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia.American journal of human genetics, 92 5
Journal of Thoracic Oncology • Volume 9, Number 11, November 2014 Letters to the Editor adopted for investigating noncalcified mediastinum, bilateral pulmonary nod- How to Minimize 2,4 nodules, and when positive cases are ules, and mediastinal lymphadenopathy Harms of Lung Cancer routinely discussed at multidisciplinary (Fig. 1). Lung biopsy and positron emis- meetings. sion tomography scan confirmed stage Screening Our change in FP definition may IV (T4N2M1a) squamous cell carcinoma be important because the low specific- of the lung. Tumor tissue samples ana- ity characteristic of the old FP defini- lyzed locally using Multiplex polymerase To the Editor: tion may adversely affect the perception chain reaction/mass spectroscopy did not I appreciated the recent editorial of the public and health policy-makers reveal activating mutations in the panel of Menezes and Roberts on the harms regarding the risks and benefits of lung of genes tested (Table 1). of lung cancer screening. I also appre- cancer screening. Because of the contraindication ciated their comments on our paper of DNA cross-linking agents in the set- published in the same issue. I agree ting of FA, the patient initially received that we need to identify strategies to Giulia Veronesi, MD reduced doses of gemcitabine and mitigate the negative physical and psy- Division of Thoracic Surgery
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Nov 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.